-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1303 Incidence of Allergic Reactions to Pegaspargase (PEG) Administered Intramuscularly Versus Intravenously (IM vs. IV) in Children and Young Adults with High Risk B- Lymphoblastic Leukemia (HR B-ALL): Results of Children's Oncology Group (COG) Studies AALL0232/AALL1131

Acute Lymphoblastic Leukemia: Clinical Studies
Program: Oral and Poster Abstracts
Session: 612. Acute Lymphoblastic Leukemia: Clinical Studies: Poster I
Saturday, December 5, 2015, 5:30 PM-7:30 PM
Hall A, Level 2 (Orange County Convention Center)

Wanda Salzer, MD1, Michael J. Burke, MD2,3, Eric C. Larsen, MD4*, Si Chen, MS5*, Lia Gore, MD6, Joanne M. Hilden, MD6, Mignon L. Loh, MD7, Elizabeth Raetz, MD8, Naomi J. Winick, MD9, William L. Carroll, MD10, Meenakshi Devidas, PhD5 and Stephen P Hunger, MD11

1U.S. Army Medical Research and Materiel Command, Fort Detrick, MD
2Division of Hematology/Oncology/Bone Marrow Transplantation, Medical College of Wisconsin, Milwaukee, WI
3Children's Hospital of Wisconsin, Milwaukee, WI
4Maine Children's Cancer Program, Scarborough, ME
5Department of Biostatistics, Colleges of Medicine, Public Health & Health Profession, University of Florida, Gainesville, FL
6Center for Cancer and Blood Disorders, Children's Hospital Colorado and the University of Colorado School of Medicine, Aurora, CO
7Department of Pediatrics, Benioff Children’s Hospital, University of California at San Francisco, San Francisco, CA
8Department of Pediatrics, Huntsman Cancer Institute and Primary Children's Hospital, University of Utah, Salt Lake City, UT
9University of Texas Southwestern Medical Center, Dallas, TX
10Department of Pediatrics, Perlmutter Cancer Center,, New York University Medical Center, New York, NY
11Department of Pediatrics, Children’s Hospital of Philadelphia and the University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

Introduction:  Asparaginase is a vital component of multi-agent chemotherapy for patients with HR B-ALL, but rates of allergic reactions following administration of PEG range from 3-24%.  Similar or increased rates of allergic reactions have been reported following IV vs. IM PEG when administered on varying chemotherapy backbones.  The COG trials recently changed from IM to IV administration of PEG. We report the rate of allergic reactions/anaphylaxis (Grade 3-4) following IM vs. IV PEG on sequential trials for newly diagnosed patients with HR B-ALL. 

Methods: Patients 1-30 years of age with newly diagnosed HR B-ALL were eligible for the sequential COG studies, AALL0232 and AALL1131.  We limited this analysis to non-Down Syndrome patients who received highly similar chemotherapy regimens prior to maintenance therapy, including a 4-drug Induction with 14 days of dexamethasone or 28 days of prednisone, the COG augmented Berlin-Frankfurt-Munster (BFM) Consolidation, High Dose Methotrexate during Interim Maintenance, and Delayed Intensification (DI).  Patients received a total of 5 doses of PEG (2,500 units/m2/dose) administered IM (AALL0232) or IV (AALL1131) during these phases of therapy:  Induction (n=1), Consolidation (n=2), DI (n=2). Chi square analysis of the rates of Grade 3-4 allergic reactions/anaphylaxis (Common Terminology Criteria for Adverse Events v4.0) following IM vs. IV PEG was performed.

Results: Grade 3-4 allergic reactions/anaphylaxis rates in patients receiving IM vs. IV PEG (Table) were 0.54% vs. 0.22% during Induction (p=0.10), 14.4% vs. 12.64% during Consolidation (p=0.18), and 2.1% vs. 0.97% during DI (p=0.07).

Conclusion:  Rates of Grade 3-4 allergic reactions/anaphylaxis were similar following IM vs. IV administration of PEG in patients with newly diagnosed HR B-ALL when treated on sequential COG studies, further establishing the safety of delivering IV PEG.

Table: Allergic Reactions Following IM vs IV PEG

Allergic reaction/

Anaphylaxis (Grade 3-4)

AALL0232

(IM PEG)

AALL1131

(IV PEG)

p-value

(Chi square test)

Induction

15/2771 (0.54%)

4/1797 (0.22%)

0.10

Consolidation

342/2369 (14.4%)

114/902 (12.64%)

0.18

DI

22/1060 (2.1%)

7/715 (0.97%)

0.07

 

 

Disclosures: Hunger: Spectrum Pharmaceuticals: Consultancy ; Jazz Pharmaceuticals: Consultancy ; Sigma Tau: Consultancy ; Merck: Equity Ownership .

See more of: 612. Acute Lymphoblastic Leukemia: Clinical Studies: Poster I
See more of: Acute Lymphoblastic Leukemia: Clinical Studies
See more of: Oral and Poster Abstracts
<< Previous Abstract | Next Abstract >>

*signifies non-member of ASH